clinical trial · NCT02014558
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc.·phase2·completed·n = 265
Acute Myeloid LeukemiaGilteritinibVoriconazoleMidazolamCephalexin
brief summary
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.
started
Oct 9, 2013
primary completion
Aug 4, 2017
completion
Mar 7, 2018
last updated
Dec 3, 2024
official title
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol